



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Hart et al.

Serial No.: 10/559,758

Filed: December 6, 2005

Entitled: Peptide Ligands

Examiner: (not yet assigned)

Art Unit: 1646

U.S. National Phase of: PCT/GB2004/002421

Attorney Docket No.: ABL-012.1P US

Mail Stop AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:


Transmitted herewith are: [X] an Information Disclosure Statement (IDS) under 37 CFR §§ 1.56, 1.97 and 1.98; [X] Form PTO-1449 Information Disclosure Statement; [X] photocopies of the disclosed documents, to be filed in the above-identified patent application; and [X] a return receipt post card.

PAYMENT OF FEES

[] A check in the amount of \$_____ (check no. _____) in payment of the fee for submission of an information disclosure statement transmitted herewith.

[X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR §§ 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



David G. O'Brien, Reg. No. 46,125
Leon R. Yankwich, Reg. No. 30,237
Attorneys for Applicants
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: (617) 374-3700
telefax: (617) 374-0055

Receipt date: 12/13/2006

10559758 - GAU: 1654

U.S. Serial No. 10/559,758

Atty. Docket No. ABL-012.1P US




CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

12/11/2006

Date

Meghan McFadden
Meghan F. McFadden



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hart et al.
Serial No.: 10/559,758
Filed: December 6, 2005
Entitled: Peptide Ligands

Art Unit: 1646

Examiner: (not yet assigned)

U.S. National Phase of: PCT/GB2004/002421
Attorney Docket No.: ABL-012.1P US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office .

A modified Form PTO-1449 listing the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents. This Statement is being submitted before the first Office Action on the merits pursuant to 37 C.F.R. § 1.97(b)(3). Accordingly, no fee is required with this submission.

Foreign Published Applications

DE 198 45 251, published March 9, 2000;
WO 01/58940, published August 16, 2001;
WO 02/072616, published September 19, 2002;
WO 02/057447, published July 25, 2002;
WO 03/004646, published January 16, 2003;
WO 03/008537, published January 30, 2003;
WO 03/094974, published November 20, 2003;
WO 91/18010, published November 28, 1991;
WO 98/44121, published October 8, 1998;

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.B./

Foreign Published Applications Continued

WO 98/54347, published December 3, 1998.

Other Documents


Bachman et al., *J. Mol. Med.*, 76: 126-132 (1998);
Bandyopadhyay, *J. Biol. Chem.*, 274: 10163-10172 (1999);
Bettinger et al., *Bioconjugate Chem.* 10: 558-561 (1999);
Boer et al., *J. Med. Chem.*, 44: 2586-2592 (2001);
Brandao, *Vaccine*, 2268-2272 (2003);
Boussif et al., *Proc. Natl. Acad. Sci. USA*, 92(16): 7297-7301 (1995);
Castilho et al., *Biotechnol. Prog.*, 18: 776-781 (2002);
Chowdhury et al., *J. Biological Chemistry*, 268(15): 11265-11271 (1993);
Cole-Strauss et al., *Science*, 273: 1386-1389 (1996);
Cruz et al., *J. Biotechnol.*, 96: 169-183 (2002);
Curiel et al., *Proc. Natl. Acad. Sci. USA*, 88: 8850-8854 (1991);
Durocher et al., *Nucleic Acids Res.*, 30(2): E9 (2002);
Ehsan et al., *J. Thorac. Cardiovasc. Surg.*, 121: 714-722 (2001);
Ehsan et al., *Circulation*, 105: 1686-1692 (2002);
Erbacher et al., *Gene Therapy*, 6(1) 138-145 (1999);
Felgner et al., *Human Gene Therapy*, 8: 511-512 (1997);
Goncz et al., *Hum. Mol. Genet.*, 7: 1913-1919 (1998);
Groth et al., *Proc. Natl. Acad. Sci. USA*, 97: 5995-6000 (2000);
Han et al., *Biol. Pharm. Bull.*, 22(8): 836-840 (1999);
Ivanenkov et al., *Biochimica et Biophysica Acta*, 1448(3): 463-472 (1999);
Knudsen et al., *Anti-cancer Drugs*, 8: 113-118 (1997);
Kren et al., *Nat. Med.*, 4(3): 285-290 (1998);
Krieg et al., *Nature*, 374: 546-549 (1995);
Mann et al., *Lancet*, 354: 1493-1498 (1999);
Mannion et al., *Ann. Thorac. Surg.*, 66: 1948-1952 (1998);
Morishita et al., *Proc. Natl. Acad. Sci. USA*, 92: 5855-5859 (1995);
Nicklin et al., *Mol. Ther.*, 4(6): 534-542 (2001);
Olivares et al., *Gene*, 278: 167-176 (2001);
Pereboev et al., *Gene Therapy*, 9(17): 1189-1193 (2002);
Reddy et al., *J. Pharm. Sciences*, 88: 1112-1118 (1999);

Reddy et al., *J. Controlled Release*, 64: 27-37 (2000);
Rosenkranz et al., *Experimental Cell Research*, 199: 323-329 (1992);
Shi, *TRENDS in Genetics*, 19(1) 9-12 (2003);
Stoll et al., *J. Bacteriol.*, 184(13): 3657-3663 (2002);
Thyagarajan et al., *Gene*, 244: 47-54 (2000);
Thyagarajan et al., *Mol. Cell. Biol.*, 21(12): 3926-3934 (2001);
Tillman et al., *J. Immunol.*, 162: 6378-6383 (1999);
Wade-Martins et al., *Molecular Therapy*, 7(5): 604-612 (2003);
Wang et al., *Am. J. Respir. Cell Mol. Biol.*, 22: 129-138 (2000);
Watkins et al., *Gene Therapy*, 4: 1004-1012 (1997);
Wickham et al., *Cancer Immunol. Immunother.*, 45: 149-151 (1997);
Woolf et al., *Proc. Natl. Acad. Sci. USA*, 92: 8298-8302 (1995);
Wu et al., *J. Biological Chemistry*, 262(10): 4429-4432 (1987);
Wu et al., *J. Biol. Chem.*, 266(22): 14338-14342 (1991);
Yano et al., *Human Gene Therapy*, 11: 995-1004 (2000);
Yant et al., *Nat. Genet.*, 25: 35-41 (2000);
Yoon et al., *Proc. Natl. Acad. Sci. USA*, 93: 2071-2076 (1996).

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application, and also printed on any patent issuing from the above-identified application.

Respectfully submitted:




David G. O'Brien, Reg. No. 46,125
Leon R. Yankwich, Reg. No. 30,237
Attorneys for Applicants
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: (617) 374-3700
telefax: (617) 374-0055

Receipt date: 12/13/2006

10559758 - GAU: 1654

U.S. Serial No. 10/559,758
Atty. Docket No. ABL-012.1P US




Certificate of Mailing

The undersigned hereby certifies that this correspondence and accompanying documents are being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

12/11/2006

date

Meghan McFadden
Meghan F. McFadden

Modified FORM PTO 1449 	ATTY. DOCKET NO. ABL-012.1P US	SERIAL NO. 10/559,758
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Hart et al.	
(Use several sheets if necessary)	FILING DATE December 6, 2005	GROUP 1646

REFERENCE DESIGNATION

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AA	DE 198 45 251	03/09/2000					
	AB	WO 01/58940	08/16/2001					
	AC	WO 02/072616	09/19/2002					
	AD	WO 02/057447	07/25/2002					
	AE	WO 03/004646	01/16/2003					
	AF	WO 03/008537	12/30/2003					
	AG	WO 03/094974	11/20/2003					
	AH	WO 91/18010	11/28/1991					
	AI	WO 98/44121	10/08/1998					
	AJ	WO 98/54347	12/03/1998					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Bachman et al., J. Mol. Med., 70: 126-132 (1998)
	AL	Bandyopadhyay, J. Biol. Chem., 274: 10163-10172 (1999)
	AM	Bettinger et al., Bioconjugate Chem., 10: 558-561 (1999)
	AN	Boer et al., J. Med. Chem., 44: 2586-2592 (2001)
	AO	Brandao, Vaccine, 22: 2268-2272 (2003)
	AP	Boussif et al., Proc. Natl. Acad. Sci. USA, 92(10): 7297-7301 (1995)
	AQ	Castilho et al., Biotechnol. Prog., 18: 778-781 (2002)
	AR	Chowdhury et al., J. Biological Chemistry, 268(15): 11265-11271 (1993)
	AS	Cole-Strauss et al., Science, 273: 1386-1389 (1996)
	AT	Cruz et al., J. Biotechnol., 96: 169-183 (2002)
	AU	Curiel et al., Proc. Natl. Acad. Sci. USA, 88: 8850-8854 (1991)
	AV	Durocher et al., Nucleic Acids Res., 30(2): E9 (2002)
	AW	Ehsan et al., J. Thorac. Cardiovasc. Surg., 121: 714-722 (2001)
	AX	Ehsan et al., Circulation, 105: 1686-1692 (2002)
	AY	Erbacher et al., Gene Therapy, 6(1): 138-145 (1999)
	AZ	Felgner et al., Human Gene Therapy, 8: 511-512 (1997)

BA	Goncz et al., <i>Hum. Mol. Genet.</i> , 7: 1913-1919 (1998)
BB	Groth et al., <i>Proc. Natl. Acad. Sci. USA</i> , 97: 5995-6000 (2000)
BC	Han et al., <i>Biol. Pharm. Bull.</i> , 22(8): 836-840 (1999)
BD	Ivanenkov et al., <i>Biochimica et Biophysica Acta</i> , 1448(3): 403-472 (1999)
BE	Knudsen et al., <i>Anti-cancer Drugs</i> , 8: 113-118 (1997)
BF	Kron et al., <i>Nat. Med.</i> , 4(3): 285-290 (1998)
BG	Krieg et al., <i>Nature</i> , 374: 540-543 (1995)
BH	Mamm et al., <i>Lancet</i> , 354: 1493-1498 (1999)
BI	Mannion et al., <i>Ann. Thorac. Surg.</i> , 66: 1048-1052 (1998)
BJ	Morishita et al., <i>Proc. Natl. Acad. Sci. USA</i> , 92: 5855-5859 (1995)
BK	Nicklin et al., <i>Mol. Ther.</i> , 4(6): 534-542 (2001)
BL	Olivares et al., <i>Gene</i> , 278: 167-176 (2001)
BM	Pereboev et al., <i>Gene Therapy</i> , 9(17): 1189-1193 (2002)
BN	Reddy et al., <i>J. Pharm. Sciences</i> , 88: 1112-1118 (1999)
BO	Reddy et al., <i>J. Controlled Release</i> , 64: 27-37 (2000)
BP	Rosenkranz et al., <i>Experimental Cell Research</i> , 199: 323-329 (1992)
BQ	Shi, <i>TRENDS in Genetics</i> , 19(1): 9-12 (2003)
BR	Stoll et al., <i>J. Bacteriol.</i> , 184(19): 5657-5665 (2002)
BS	Thyagarajan et al., <i>Gene</i> , 244: 47-54 (2000)
BT	Thyagarajan et al., <i>Mol. Cell. Biol.</i> , 21(12): 3926-3934 (2001)
BU	Tillman et al., <i>J. Immunol.</i> , 162: 6378-6383 (1999)
BV	Wade-Martins et al., <i>Molecular Therapy</i> , 7(5): 604-612 (2003)
BW	Wang et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , 22: 120-128 (2000)
BX	Watkins et al., <i>Gene Therapy</i> , 4: 1004-1012 (1997)
BY	Wickham et al., <i>Cancer Immunol Immunother</i> , 45: 149-151 (1997)
BZ	Woolf et al., <i>Proc. Natl. Acad. Sci. USA</i> , 92: 8298-8302 (1995)
CA	Wu et al., <i>J. Biological Chemistry</i> , 262(10): 4420-4432 (1987)
CB	Wu et al., <i>J. Biol. Chem.</i> , 266(22): 14338-14342 (1991)
CC	Yano et al., <i>Human Gene Therapy</i> , 11: 995-1004 (2000)
CD	Yant et al., <i>Nat. Genet.</i> , 25: 35-41 (2000)
CE	Yoon et al., <i>Proc. Natl. Acad. Sci. USA</i> , 93: 2071-2076 (1996)
CCV EXAMINER	/Christina Bradley/ DATE CONSIDERED 07/06/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

sheet 3 of 3